x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012852
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human SPAR protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SPAAR |
| UniProt No. | A0A1B0GVQ0 |
| Gene ID | 158376 |
| Gene Description | Small regulatory Polypeptide of Amino Acid Response is a polypeptide, encoded by the lncRNA LINC00961 gene and is localized in late endosomal and lysosomal membranes. SPAR binds to the lysosomal v-ATPase complex in addition to ragulator, RagA and RagC. Upon amino acid stimulation, this supercomplex activates mTORC1 signaling. However, this process is inhibited by the binding of SPAR to the v-ATPase complex, as its formation prevents mTORC1 recruitment to lysosomes. SPAR downregulation and inactivation is an important focus for promoting muscle regeneration following muscle injury. This downregulation and inactivation promotes mTORC1 activation and results in myofiber maturation. In addition to muscle regeneration, SPAR downregulation and inactivation also promotes stem cell proliferation and differentiation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
